RSS
6 Jun 2023

Bold Therapeutics Presents Positive Interim Phase 2 Results for BOLD-100 in Advanced Gastric and Biliary Tract Cancer at ASCO 2023

Author: admintech | Filed under: Press Release

VANCOUVER, BC, June 6, 2023 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim results in advanced gastric and biliary tract cancer at the 2023 American Society of Clinical Oncology…

This entry was posted on Tuesday, June 6th, 2023 at 7:15 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»